| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47db618addf0f78fd218286835f4325d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2869 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate |
2016-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74509506ed03b77c013791d440ee1f12 |
| publicationDate |
2016-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2016222684-A |
| titleOfInvention |
Combination pharmaceutical composition and method for treating diabetes and metabolic disorders |
| abstract |
Disclosed is a pharmaceutical composition for administration to a patient suffering from diabetes and other metabolic disorders. A pharmaceutical composition comprising a) an activation-enhancing antibody against a human insulin receptor and b) an activation-enhancing antibody against endothelial NO synthase. A pharmaceutical composition comprising: a) an activation-enhancing antibody against a C-terminal fragment of human insulin receptor β-subunit; and b) an activation-enhancing antibody against endothelial NO synthase. Enhanced activation of the C-terminal fragment of the human insulin receptor β-subunit in the form of a mixture of a pharmaceutically acceptable solid carrier and a) a C12, C30, and C200 homeopathic dilution impregnated with the solid carrier And b) an activation-enhancing antibody to endothelial NO synthase in the form of a mixture of C12, C30, and C200 homeopathic dilutions permeated into the solid support. [Selection] Figure 1 |
| priorityDate |
2010-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |